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ABSTRACT 
 
A subset of CD4+ T cells named T helper (Th)22 cells play some pathogenic roles in 
some autoimmune disorders such as type 1 diabetes (T1D). We aimed to study the 
correlation between the circulatory number of these cells and serum levels of its related 
cytokines with T1D as well as diabetic complications including metabolic control, 
atherosclerosis, and nephropathy. 
Fortynine patients with T1D and 43 healthy controls underwent the assessment of 
circulatory number of Th22 cells (by flow cytometry), serum level of Th22 related cytokines 
including Interleukin-22 (IL-22), Interleukin-10 (IL-10), Transforming growth factor-β 
(TGF-β), Tumor necrosis factor-α (TNF-α) (by ELISA) and carotid intima-media thickness 
(cIMT) measurement (by doppler ultrasonography). In addition, fasting blood and urine 
samples were taken to measure levels of hemoglobin A1C, lipid profile, cell blood count 
(CBC), serum and urine creatinine and urine protein in all participants. 
Th22 frequency and serum levels of IL-22 and TNF-α in patients were significantly 
higher than those in controls (p<0.001). Serum levels of IL-10 and TGF-β in healthy 
individuals were higher than those in patients (p<0.001). None of the Th22 related markers 
had a significant correlation with diabetic complications. There was only a significant effect 
of IL-22 on HbA1C variations.  
Th22 pathway has a significant correlation with T1D but not with its complications of 
cIMT and Urine Albumin/Creatinine Ratio (UACR). We report that Th22 pathway is not a 
good prognostic as well as diagnostic marker of early macrovascular complications in T1D. 
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INTRODUCTION 
 
Type 1 diabetes (T1D) is perceived as an  
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insulin-producing beta cells, in the pancreatic islets.
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The exact cause of the autoimmune attack in this  
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debilitating illness remains unknown but T-cells appear 
to play a pivotal role in the destruction process of the 
insulin-producing beta cells and the potential 
contributions of T helper (Th1/Th2) subsets in the 
disease process seem to be substantial.
2
 These cells can 
participate in disease process through different ways. 
However, aberrations of their cytokines appear to play 
a pivotal role in the pathogenesis of  T1D. Recently, 
there has been an increase in researches involving Th22 
effector subpopulations of T lymphocytes.  
Interleukin-22 (IL-22), as signature cytokine of 
Th22 cells, belongs to the Interleukin 10 (IL-10) 
cytokine family and has some roles in different 
autoimmune conditions.
3
 IL-10 by itself plays 
regulatory as well as tolerogenic roles in T1D. In this 
regard, early systemic treatment with exogenous 
murine IL-10 can inhibit T1D in non-obese diabetes 
(NOD) mice.
4
 Confirming such regulatory role, IL-10 
and the other regulatory and tolerogenic cytokine, 
Transforming growth factor-β (TGF-β), have been 
reported to be associated with benign insulitis; whereas 
the inflammatory cytokine of tumor necrosis factor-α 
(TNF-α is associated with destructive form of insulitis.5 
The uncertain status of the production of both of IL-10 
(as an anti-inflammatory cytokine) and of IL-22 (as an 
inflammatory cytokine) from Th22 cells is essential to 
be cleared in the inflammatory autoimmune state of 
diabetes. Also considering the both decreased 
production and function of regulatory T cells (as main 
producer of TGF-β) in autoimmune conditions6 such as 
T1D,
7
 the investigators have hypothesized that there is 
a decreased production of IL-10
8
 and TGF-β in 
accordance with Th22 pathway function in T1D. 
Diabetic complications progress due to 
inflammation which is originated from multiple 
pathways and mechanisms.
9
 The relationship between 
metabolic control and development of chronic adverse 
complications of T1D has always been a big concern 
over the years; and nowadays the main indicator of 
long-term glycemic control in T1D and its 
complications is the glycosylated hemoglobin 
(HbA1c).
10
  
Coronary atherosclerotic heart disease (CHD) is one 
of the major concerns in T1D. The systemic chronic 
inflammation triggered by immune system activity has 
been postulated to bridge the increased risk of 
cardiovascular disease and T1D. Th22 cells might play 
an independent role in CHD and represent a novel 
proxy for cardiovascular risks in diabetes.
11
 Increased 
common intima media thickness (cIMT), measured by 
ultrasound, is an early and strong predictor of 
atherosclerotic changes leading to future vascular 
events.
12
 Considering diabetes as the main risk factor of 
atherosclerosis,
13
 a few investigators have indicated 
that children,
14
 adolescents and adults
11
 with T1D have 
significantly higher cIMT than that the healthy people. 
Diabetic nephropathy (DN) is the other diabetic 
complication which may cause end-stage renal 
disease.
15
 DN is characterized by basement membrane 
thickening, expansion of the mesangial cells, reduced 
filtration, albuminuria, and ultimately renal failure.
16
 
Albuminuria is a well-established independent 
predictor of diabetic nephropathy as well as 
cardiovascular morbidity and mortality in both type 1 
and type 2 diabetic patients.
17
 
In present study, we aimed to identify the 
circulatory frequency of Th22 cells and the serum level 
of its related cytokines including IL-22, IL-10, TGF-β, 
and TNF-α in type 1 diabetic patients. We also 
evaluated the potential of such biomarkers as 
diagnostic and prognostic tools of T1D complications. 
 
MATERIALS AND METHODS 
 
Patients and Sampling Protocol 
A total of 49 people suffering from T1D for at least 
5 years with no yet-known diabetic complications and 
43 sex, age and BMI-matched healthy controls were 
enrolled in our case-control study. Control subjects 
with no family history of diabetes were recruited from 
local Blood Donation Organization. The diagnosis of 
T1D was based on the American Diabetes 
Association’s criteria. Exclusion criteria were liver, 
kidney, rheumatoid, endocrine, cardiovascular, and 
metabolic diseases; familial cardiovascular diseases; 
cancer; and a history of using antihypertensive or lipid-
lowering medications as well as smoking. 
The protocol was approved by the local Committee 
of Ethics (N. 92143) and was in accordance with the 
Helsinki Declaration. Written informed consent was 
obtained from all participants older than 16 years and 
in the case of younger ones from their parents/ 
guardians. 
Blood and urine samples were drawn at 08:00-10:00 
in the morning after 12 hours overnight fasting. CBC 
and serum levels of HbA1c, creatinine, and lipids 
profile were evaluated using standard laboratory 
methods. An automatic cell counter Sysmex K4500 
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(Japan) counted blood cells and an 
immunoturbidometric method of Bayer Diagnostics 
Europe Ltd (Ireland) protocol measured HbA1c levels. 
Lipid profile was assessed using end-point enzymatic 
methods throughBeckman Instruments, Fullerton, 
California's protocol. Height and weight were measured 
using a wall-mounted stadiometer to the nearest 0.1 cm 
and an electric digital scale to the nearest 0.1 kg, 
respectively. 
 
Ultrasonography 
Having left all participants in supine position for at 
least 10 min in a quiet room at 22
o
C, a radiologist 
unaware from the subject’s clinical details performed 
their ultrasonography according to standardized 
scanning protocol for the right and left common carotid 
arteries to determine the cIMT using a medison v20 
equipped with a linear 11 MHZ transducer 
(Medison/Samsung Medicine System GmbH, South 
Korea). On each common carotid artery, a 2cm 
segment proximal to the bulb region on far wall of the 
carotid was scanned by at least 100 points. All images 
were taken at end-diastole and then stored digitally for 
subsequent off-line analysis. Computer software 
analyzed the IMT distance automatically via 
arithmetically calculating a mean of the thickenings of 
the 2 above-mentioned segments. 
 
Flow Cytometric and ELISA Analysis 
Fresh peripheral blood mononuclear cells (PBMCs) 
were separated from 2 ml of anti-coagulated blood by 
Ficoll-Hypaque (Lymphodex, innoTRAin, Germany) 
density gradient centrifugation. At least one million 
PBMCs were stimulated in a duplicated form in the 
presence of PMA (50 ng/mL, Sigma) and ionomycin (1 
μg/mL, Sigma) in a RPMI 1640 media (Invitrogen) at a 
37
 o
C
 
incubator with 5% CO2 for 2 hours. Then the 
cells were cultured for another 4 hours in the presence 
of Brefeldin (0.5μg/mL, Sigma). Negative control was 
produced via culture only in the RPMI 1640 media. 
Stimulated cells firstly were stained by antiCD4-APC 
(Allophycocyanin) (eBioscience, USA) and after 
fixation/permeablization (eBioscience, USA) were 
stained by antiIL-22-PE (eBioscience, USA) according 
to the manufacturer’s instructions. The percentages of 
CD4
+
IL-22
+
 cells were analyzed by a 3-color flow-
cytometry using BD FACScalibur flow-cytometry (BD, 
USA). Lymphocytes were gated on the basis of light 
scattering properties at least 100,000 events were 
obtained for each patient sample. Serum levels of IL-
22, IL-10, TGF-β, and TNF-α cytokines were measured 
through sandwich Elisa method according to 
manufacturer’s instructions (eBioscience, USA). 
 
Statistical Analysis 
The results were expressed as mean±SD. The 
normality of the quantitative variables was confirmed 
by Kolmogorov-Smirnov test. The groups were 
compared by chi square test for gender of participants 
and independent t-tests for quantitative variables. 
Pearson's coefficient was determined for correlating 
between Th22-related immunologic factors as 
independent variables and diabetic complication 
findings as dependent variables. Also, we used multiple 
linear regression models to evaluate the effect of such 
markers on complications of T1D. Adjusted R square 
was used as a criterion of goodness of fit test and p>0.2 
was considered as an exclusion criterion from the 
model. All analyses were made by the SPSS package 
(Version 16.0. Chicago, SPSS Inc.). 
 
RESULTS 
 
Basic and clinical characteristics of the study 
groups are shown in Table 1. Th22 frequency (1.6±1.05 
vs 0.7±0.5) and serum levels of IL-22 (33.57±16.23 vs 
20.04±10.37) and TNF-α (6.41±4.28 vs 3.21±2.26) 
were significantly higher in patients than those in 
controls (p<0.001). IL-10 (7.83±4.67 vs 4.15±2.57) and 
TGF-β (5.43±2.9 vs 2.01±1.37) levels were higher in 
healthy individuals than those in patients (p<0.001). 
T1D patients showed a significantly greater HbA1c 
(7.34±1.24 vs. 4.73±0.73), cIMT (0.457±0.009 vs 
0.392±0.006) and UACR (10.8±8.57 vs 3.01±2.64) 
than those in the control group (p<0.001). We found a 
strong positive correlation between the Th22 frequency 
and serum levels of IL-22 in the patients (r=0.894, 
p<0.001). Such correlation was not found in control 
group (r=0.186, p=0.231). 
Bivariate correlation showed no significant 
relationship between different Th22 related biomarkers 
and cIMT, UACR and HbA1c as indicators of diabetic 
complications including diabetic atherosclerosis, 
diabetic nephropathy, and poor metabolic control, 
respectively, in both control and patient groups (Table 
2). 
Modeling the effect of different markers on the 
prediction of diabetic complications through multiple 
linear regression analysis, we found that the diabetes 
itself is the most important factor affecting on HbA1c, 
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UACR and cIMT changes. Other important factor 
affecting on HbA1c was IL-22 (p=0.034), while there 
was no linear relation between HbA1c and other 
inflammatory factors (p>0.05). Effective factors on 
cIMT were diabetes (group), age and sex (p<0.05) and 
there was not any linear relation between IL-22 and 
cIMT as well as UACR. Such modeling showed that 
the only important factor affecting on UACR is 
diabetes (group) (p<0.001). It means that some other 
factors affect UACR except Th22 and IL-22. Such 
model also showed that both serum levels of IL-22 and 
diabetes are effective factors on the increase of HbA1C 
(Table 3).  
 
Table 1. Basic and clinical characteristics of type1 diabetic patients and healthy control group 
Variables Healthy controls (n=43) T1D (n=49) p value 
Age (years) 10.95±3.83 12.20±3.86 0.12 
Gender (male/female) 21/22 22/27 0.7 
Duration of diabetes (months) - 73.22±5.9 - 
BMI (kg/m2) 21.02±4.25 21.23±4.6 0.826 
HbA1c (%) 4.73±0.73 7.34±1.24 <0.001 
Th22 frequency (%) 0.72±0.5 1.61±1.05 <0.001 
IL-22 (pg/mL) 20.04±10.37 33.57±16.23 <0.001 
TNF-α (pg/mL) 3.21±2.26 6.41±4.28 <0.001 
IL-10 (pg/mL) 7.83±4.67 4.15±2.57 <0.001 
TGF-β (pg/mL) 5.43±2.9 2.01±1.37 <0.001 
eGFR (mL/min/1.73m2) 87.1±34.4 90.6±27.8 0.64 
UACR (mg/g Cr) 3.01±2.64 10.8±8.57 <0.001 
Urine protein (mg/dl) 2.01±2.17 1.69±1.52 0.538 
Urine creatinine (mg/dl) 265.73±158.60 136.58±57.97 <0.001 
Mean Intimae 
Media 
Thickness 
(mm) 
Sex Male 0.4±0.008 0.46±0.01 0.001 
Female 0.39±0.008 0.46±0.01 <0.001 
p value 0.43 0.97 - 
Age ≤12 years (n) 0.39±0.01 0.46±0.01 0.008 
12 years (n) 0.38±0.006 0.45±0.01 0.001 
p value 0.48 0.53 - 
Total 0.392±0.006 0.457±0.009 <0.001 
T helper 22; Interleukin 22; Tumor Necrosis Factor-α; Interleukin 10; Transforming Growth Factor-β 
 
Table 2. Correlation of T helper22-related biomarkers and diabetic complications in 2 groups of type-1 diabetic patients and 
healthy controls 
Group Variable Th22 
r (p value) 
IL-22 
r (p value) 
IL-10 
r (p value) 
TNF-α 
r (p value) 
TGF-β 
r (p value) 
Control HbA1c (%) 0.056 (0.72) -0.094(0.54) 0.039(0.80) 0.085(0.59) 0.236(0.12) 
Mean cIMT -0.126(0.52) 0.217(0.26) 0.068(0.73) -0.210(0.28) -0.129(0.51) 
UACR 0.068(0.76) 0.101(0.65) -0.105(0.64) -0.066(0.77) -0.192(0.39) 
Patients HbA1c (%) 0.091(0.53) 0.254(0.07) -0.184(0.20) 0.119(0.41) -0.091(0.53) 
Mean cIMT 0.020(0.91) 0.116(0.54) -0.243(0.19) 0.079(0.68) -0.132(0.48) 
UACR 0.059(0.68) 0.060(0.68) -0.095(0.51) 0.164(0.26) -0.030(0.84) 
T helper 22; Interleukin 22; Tumor Necrosis Factor-α; Interleukin 10; Transforming Growth Factor- β 
Independent variables: Th22, IL22, IL10, TNF-α, TGF-β 
Dependent variables: HbA1c (%), Mean cIMT, UACR  r= correlation coefficient 
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Table 3. Linear multiple regression analysis for evaluating the effect of T helper22-related biomarkers on diabetic 
complications 
Dependent 
Variables 
Explanatory  variables B SE 
Wald 
Statistic 
95% CI p value Adjusted R2 
HbA1c 
Constant 3.759 0.449 8.371 (-2.87 , 4.64) <0.001 
0.633 
Group*(Diabetes) 2.619 0.269 9.745 (2.09,3.15) <0.001 
Sex(male) 0.350 0.215 1.627 (-0.07,0.77) 0.107 
IL-22* 0.019 0.009 2.160 (0.001,0.036) 0.034 
TGF 0.077 0.056 1.357 (-0.328,0.187) 0.178 
cIMT 
Constant 0.358 0.023 15.495 (0.313,0.403) <0.001 
0.285 
Group*(Diabetes) 0.031 0.015 2.118 (0.001,0.06) 0.039 
Age* 0.003 0.001 2.816 (0.001,0.005) 0.007 
Sex(male)* 0.042 0.013 3.111 (0.016,0.068) 0.003 
IL-22 0.001 0.0006 1.551 (-0.000,0.002) 0.127 
UACR 
Constant 3.002 1.556 1.929 (0.048,6.05) 0.058 
0.189 
Group*(Diabetes) 7.805 1.873 4.167 (4.13,11.4) <0.001 
Interleukin 22; Transforming Growth Factor- β 
 unstandardized coefficient; it explains both potency and kind (direct or inverse) of its relation on dependent variable. It is the mathematical 
weightings of the explanatory variables in the equation 
SE: standard Error of B; it is an estimated precision of the coefficients 
95% CI: 95% confidence intervals for the coefficients 
Wald statistic: the estimate of the coefficient divided by its standard error 
Adjusted R2: the adjusted R-squared; it compares the explanatory power of regression models that contain different numbers of predictors. 
* their effects on diabetic complications is statistically meaningful. 
 
 
DISCUSSION 
 
Type 1 diabetes (T1D) is perceived as an 
autoimmune disease resulting from the immune-
mediated destruction of pancreatic β cells.18 Both the 
immune regulation and immune response are involved 
in the pathogenesis of T1D, in which infiltrated 
different immune cells take part in the damage of β 
cells.
19
 
Discovering different subsets of CD4
+
 T cells,
20
 
investigators have identified a novel subset of T helper 
(Th) cells, Th22, which is induced by TNF-α as well as 
TGF-β cytokines and plays an emerging role in many 
inflammatory and autoimmune disorders
21
 such as 
T1D.
22
 Th22 subset is identified by secretion of various 
cytokines such as tumor necrosis factor-α (TNF-α), IL-
10, and the most important one which is IL-22.
3
 Th22 
plays dual roles in immune system. From one side it is 
protective against several infectious diseases, and from 
the other side it might be pathogenic. Both 
characteristics are invented from its inherent pro-
inflammatory features; it would further elevated when 
IL-22 is produced together with other pro-inflammatory 
cytokines, in particular IL-17.
23
 
We found that T1D patients have higher frequencies 
of Th22 lymphocytes and higher plasma IL-22 levels 
compared to healthy individuals. Along with ours, little 
studies
22
 showed a significantly elevated of such cells 
indicating their contribution in the pathogenesis of T1D 
itself and its complications. Interestingly, IL-22 shows 
dual effects in different pathologies.
24
 For example, IL-
22 could potentially induce regeneration of β cells and 
prevent their apoptosis
25
 to preserve insulin levels in 
T1D. Therefore, its elevation may act as a 
protective/compensatory factor to relieve the disease 
progression. Such role has been explained in some 
other inflammatory states in which IL-22 repairs the 
tissue via induction of epithelial cell proliferation and 
survival. In this way, IL-22 prevents tissue destruction 
in several mouse models of hepatitis,
26
 colitis,
27,28
 and 
graft versus host disease.
29
 In contrast, IL-22 induces 
inflammatory molecules and in this way its increased 
concentration has been shown in a variety of human 
diseases including psoriasis,
30
 rheumatoid arthritis,
31
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inflammatory bowel diseases‚ influenza and human 
immunodeficiency virus, which collectively afflict 
millions of people worldwide.
32
 
Considering such paradoxical effects, we should 
introduce Th22 pathway having detrimental or 
beneficial effects on human islet cells. The fate of such 
different potentials may be from the duration of the 
disease in which the autoimmune attack of Th22 
pathway may be weakened after a longer duration.
22
 
High glucose increases the risk of late, potentially 
life-threatening complications of T1D. Analyzing 
CD4+IL-22+Th22 subsets, we and others
33
 found that 
T1D patients with higher levels of IL-22 (as the main 
cytokine of Th22) had greater HbA1c values. In this 
regard, our findings highlight the role of IL-22 
immunity in the pathogenesis of human T1D and its 
metabolic complications. 
We also found that elevated systemic IL-10 and 
TGF-β were limited to healthy individuals suggesting a 
potential therapeutic role for these cytokines in the 
autoimmune disease of T1D. 
To our knowledge, this is the first study 
demonstrating the changes of Th22 subset and its 
related cytokines in T1D and its complications. The 
limitation of our study was lack of monitoring such 
changes longitudinally. This limitation allowed just a 
cross-sectional analysis of only limited robustness. 
Secondly, functional assays which provide further 
information on the possible immune-regulatory 
mechanism of Th22 pathway were not performed. As 
further studies emerge to address current limitations, 
improved therapies targeting such molecules may 
ultimately transit from treating the pathology to 
prevention. 
Our data demonstrated that while the elevated 
circulatory Th22 frequencies are correlated with IL-22 
serum levels in T1D patients, neither Th22 nor IL-22 
have linear correlation with metabolic, cardiovascular, 
and nephropathic complications of T1D. We report that 
Th22-related biomarkers are not good prognostic as 
well as diagnostic indicators of T1D complications. 
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